Baron, M.D., Amylin Pharmaceuticals, Inc., 9373 Towne Centre Drive,San Diego, California 92121. E-mail: abaron@amylin.com. This work was supported by Amylin Pharmaceuticals, Inc. (San Di- ego, CA). References 1.Kahn SE, Porte Jr D 1997 Pathophysiology of type II diabetes mellitus. In: Porte Jr D, Sherwin RS, eds. Diabetes mellitus, ed 5. Stamford, CT: Appleton andLange; 487 –512 2.Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS 1999 Racial and ethnic differences in glycemic control of adults with type 2 diabetes. DiabetesCare 22:403 –408 3.Inzucchi SE 2002 Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287:360 –372 4.UK Prospective Diabetes Study Group 1995 UK Prospective Diabetes Study 16. Overview of 6 years ’therapy of type II diabetes: a progressive disease. Diabetes 44:1249 –1258 5.UK Prospective Diabetes Study Group 1998 Intensive blood-glucose control